(Q38036541)

27 August 2017

Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms (English)

1 reference

27 August 2017

1 reference

1 reference

Whay Kuang Chia

1

1 reference

27 August 2017

Raghib Ali

series ordinal

2

1 reference

27 August 2017

Han Chong Toh

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

21 August 2012

1 reference

Nature Reviews Clinical Oncology

27 August 2017

1 reference

27 August 2017

9

1 reference

27 August 2017

10

1 reference

27 August 2017

561-570

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.137

27 August 2017

0 references

cites work

Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Capecitabine as adjuvant treatment for stage III colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Adjuvant therapy in colon cancer--what, when and how?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Tumorigenesis and the angiogenic switch

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

The future development of bevacizumab in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Cerebral hemorrhage, warfarin, and intravenous tPA: the real risk is not treating.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

The role of aspirin in cancer prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Aspirin use and survival after diagnosis of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Use of aspirin postdiagnosis improves survival for colon cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

A randomized trial of aspirin to prevent colorectal adenomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Aspirin and folic acid for the prevention of recurrent colorectal adenomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Celecoxib for the prevention of sporadic colorectal adenomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Celecoxib for the prevention of colorectal adenomatous polyps

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Rofecoxib reduces polyp recurrence in familial polyposis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Aspirin dose and duration of use and risk of colorectal cancer in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Aspirin use and lung, colon, and breast cancer incidence in a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Aspirin and the Risk of Colorectal Cancer in Women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Aspirin and the prevention of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

New data on aspirin and colorectal cancer brings calls for new guidelines, more research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

The NCI60 human tumour cell line anticancer drug screen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Predictive factors for pulmonary metastases after curative resection of rectal cancer without preoperative chemoradiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Inguinal lymph node metastases are recognized with high frequency in rectal adenocarcinoma invading the dentate line. The histological features at the invasive front may predict inguinal lymph node metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Mesorectal grades predict recurrences after curative resection for rectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Colorectal cancer: a tale of two sides or a continuum?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Epigenetics and colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Molecular classification and correlates in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

CpG island methylation in colorectal cancer: past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Selection bias in observational and experimental studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Final report on the aspirin component of the ongoing Physicians' Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

International comparisons of cumulative risk of colorectal cancer, from cancer incidence in five continents vol. VIII.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

A strategy for distinguishing optimal cancer subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

The immune contexture in human tumours: impact on clinical outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Cancer immunology--analysis of host and tumor factors for personalized medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Methylation of polycomb target genes in intestinal cancer is mediated by inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Immunity, Inflammation, and Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Epithelial metaplasia: adult stem cell reprogramming and (pre)neoplastic transformation mediated by inflammation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Inflammation and EMT: an alliance towards organ fibrosis and cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Contribution of platelets to tumour metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Fibrin and Activated Platelets Cooperatively Guide Stem Cells to a Vascular Injury and Promote Differentiation Towards an Endothelial Cell Phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

Tumor self-seeding by circulating cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.137

The CpG island methylator phenotype in colorectal cancer: progress and problems

31 March 2020

1 reference

12 December 2020

A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker

1 reference

12 December 2020

Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.

1 reference

12 December 2020

Sulindac causes regression of rectal polyps in familial adenomatous polyposis

1 reference

12 December 2020

Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial

1 reference

12 December 2020

A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer.

1 reference

12 December 2020

Aspirin use and risk of fatal cancer

1 reference

12 December 2020

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial

1 reference

12 December 2020

10.1038/NRCLINONC.2012.137

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference